AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma

Glioblastoma (GB) is the most common primary brain tumor, which is characterized by low immunogenicity of tumor cells and prevalent immunosuppression in the tumor microenvironment (TME). Targeted local combination immunotherapy is a promising strategy to overcome these obstacles. Here, we evaluated...

Full description

Bibliographic Details
Main Authors: M.I. Strecker, K. Wlotzka, F. Strassheimer, B. Roller, G. Ludmirski, S. König, J. Röder, C. Opitz, T. Alekseeva, J. Reul, L. Sevenich, T. Tonn, W.S. Wels, J.P. Steinbach, C.J. Buchholz, M.C. Burger
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
Immunotherapy
tumor targeting
checkpoint inhibition
CAR-NK cell
adeno-associated virus
HER2
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2127508

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2127508

Similar Items